What Fleco Treats: Main Uses and Benefits

Fleco contains the active ingredient flecainide acetate, a medication classified as a Class IC antiarrhythmic agent. It is primarily used to manage and prevent certain types of irregular heartbeats, known as arrhythmias, in patients without structural heart disease.

Primary Indications

Fleco is indicated for the prevention and suppression of specific supraventricular and ventricular arrhythmias. Its main applications include:

• Paroxysmal Atrial Fibrillation (PAF): Management of intermittent episodes of rapid, irregular heartbeats originating in the upper chambers of the heart.
• Paroxysmal Supraventricular Tachycardias (PSVT): Prevention of sudden episodes of rapid heart rates, including atrioventricular nodal re-entrant tachycardia and Wolff-Parkinson-White (WPW) syndrome.
• Ventricular Arrhythmias: Suppression of documented life-threatening ventricular tachycardias, which involve rapid heart rhythms originating in the lower chambers of the heart.

Mechanism of Action

The medication works by regulating the electrical signals in the heart. It binds to and blocks sodium channels in the cardiac cell membranes, which slows the conduction of electrical impulses. This stabilization of the heart's electrical activity helps to maintain a normal, steady rhythm and prevents the onset of abnormal beats.

Therapeutic Benefits

The goal of treatment with Fleco is to restore and maintain a stable heart rhythm (sinus rhythm). By successfully managing heart rhythm disorders, the medication provides several clinical benefits:

• Rhythm Stabilization: Reducing the frequency and duration of arrhythmia episodes.
• Symptom Management: Alleviating physical symptoms associated with irregular heartbeats, such as palpitations, shortness of breath, and fatigue.
• Quality of Life: Improving the patient's ability to engage in daily activities by reducing the unpredictability of heart rhythm disturbances.

Fleco is typically reserved for patients with symptomatic arrhythmias where other treatments have been ineffective or are not tolerated, and it is specifically used in cases where there is no evidence of significant underlying structural heart damage or recent myocardial infarction.

Regulatory References

1. DailyMed NLM NIH database

Eligibility for Fleco: Official Regulatory Rules

Flecainide acetate (Fleco) eligibility is defined by strict regulatory criteria concerning the patient’s underlying heart health and organ function. Use is primarily restricted to adult patients for specific arrhythmias in the absence of structural heart disease.

Population Status	Regulatory Classification (Summary)
Absolutely Contraindicated	Patients with structural heart disease (e.g., recent Myocardial Infarction, severe LV dysfunction) and those with pre-existing Second- or Third-Degree AV Block or Bifascicular Block unless a pacemaker is present [DailyMed NLM NIH]. Use is also not recommended in Chronic Atrial Fibrillation [DailyMed NLM NIH].
Restricted/Conditional Use	Patients with severe renal impairment (Creatinine Clearance le 35 mL/ min) or hepatic impairment. Use in these groups requires caution and strict plasma level monitoring due to reduced drug clearance [emc]. Electrolyte imbalances must be corrected before treatment initiation [Mayo Clinic].
Age and Developmental Status	Pediatric (Under 12): Use is not established and not generally recommended [emc]. Older Adults: Elimination may be slower, requiring caution [emc]. Pregnancy/Lactation: Should only be used if the potential benefit outweighs the risk [emc].

This eligibility structure limits Fleco's use to selected patient populations where the risk of proarrhythmia is carefully controlled by the absence of specific underlying heart conditions, as dictated by governmental prescribing information.

The official regulatory information for Flecainide acetate (Fleco) strictly defines interaction patterns with other medicines and products. These constraints primarily involve pharmacokinetic effects on drug exposure and additive pharmacodynamic risks.

Formal Contraindicated Combinations

Co-administration with certain agents, including Ritonavir, Tipranavir, and the strong inhibitor Mavorixafor, is strictly prohibited by regulatory bodies. This restriction stems from the high risk of severely increasing flecainide plasma concentrations. The co-administration of Fleco with other Class I Antiarrhythmics is also generally contraindicated.

---

Metabolic and Pharmacodynamic Effects

The most documented pharmacokinetic interaction is with Amiodarone, which can increase flecainide plasma levels by two-fold or more via inhibition of its metabolism. Cimetidine is similarly documented to increase flecainide levels by approximately 30%. Pharmacodynamically, using Fleco with Beta-Adrenergic Blocking Agents (e.g., Propranolol) carries the regulatory note of potential additive negative inotropic effects. Flecainide also alters the concentration of concomitant medicines, causing a documented 13% to 19% increase in plasma levels of Digoxin.

---

Product and Population Interactions

Interaction notes extend to non-medicinal substances: the official label states that alcohol may increase the risk of dizziness. Elimination is also markedly slower in patients with significant hepatic or renal dysfunction, a factor that affects overall interaction management.

Flecainide's primary mechanism is the use-dependent blockade of the cardiac voltage-gated sodium channel ( Na v1.5). This interaction is defined by the drug binding most effectively when the channel is in its open state, meaning the blockade is greater during periods of rapid electrical activity (use-dependence). By limiting the rapid influx of sodium ions (I Na), the drug directly slows the rate of electrical depolarization and impulse conduction throughout the heart muscle.

This electrophysiological cascade results in a reduction in conduction velocity coupled with a relative prolongation of the effective refractory period (ERP). This change in parameters disrupts the necessary conditions for re-entry circuits to form, which rely on rapid, circulating electrical activity, thereby limiting the formation and propagation of these pathways.

As a physiological consequence of its influence on overall ion movement, the mechanism also affects excitation-contraction coupling, resulting in a reduction in myocardial contractility (negative inotropic effect). This change in the heart's mechanical function is an inherent physiological output of the drug's ion channel modulation profile.

How to Use Fleco (Aceclofenac 100 mg Film-Coated Tablets)

This section outlines the administration instructions for Fleco to ensure proper usage.

Administration Scope

The approved route of administration for Fleco tablets is oral. The tablets must be swallowed whole with a sufficient quantity of liquid and should not be crushed or chewed. Dosing should be administered at the lowest effective dose for the shortest possible duration.

Standard Dosing and Frequency

Regimen Element	Instruction
Standard Single Dose	100 mg (one tablet)
Standard Daily Dose	200 mg
Frequency	Twice daily (typically morning and evening)
Timing Relative to Meals	Preferably with or immediately after food

Population-Specific Adjustments

Dose modifications are specified for particular patient groups:

• Hepatic Impairment (Liver): The initial daily dose is reduced to 100 mg once daily.
• Renal Impairment (Kidney): Caution is advised; no specific dose adjustment is mandated for mild impairment.
• Pediatric Use (Under 18 years): Fleco is not recommended for use in children and adolescents due to a lack of sufficient clinical data.
• Elderly: No routine dose modification is necessary.

Procedural Summary

The usage protocol involves taking the 100 mg tablet twice daily, ensuring it is consumed whole with meals. The maximum daily dose of 200 mg should not be exceeded, and the treatment course should be re-evaluated regularly by a healthcare professional.

Research evidence / Overview of studies for Fleco

Evidence for Use in Paroxysmal Atrial Fibrillation

The main body of Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews research focuses on the compound's study in Paroxysmal Atrial Fibrillation (PAF), a condition characterized by fluctuating or episodic manifestations of an irregular, rapid heart rhythm.

Research focused on studies designed for extended observation periods for this condition. Studies monitored whether participants were able to maintain a normal sinus rhythm (NSR) and tracked the frequency and recurrence of the abnormal heart rhythm episodes over defined time intervals. These trials consistently focused on adults with recurrent, symptomatic PAF who were carefully selected to exclude those with significant structural heart disease.

Evidence for Use in Atrial Flutter and Supraventricular Tachycardia

Fleco was also evaluated in research contexts for Atrial Flutter and various types of Supraventricular Tachycardia (SVT), which are conditions associated with acute or disruptive episodes of rapid heart activity.

For Atrial Flutter, research monitored measurements related to the restoration of a normal heart rhythm (NSR) in an acute setting. Similarly, for SVT, research focused on episodes where symptoms become more noticeable, measuring the termination of the rapid rhythm and the prevention of its return over a period of time. Research describes patterns related to rhythm conversion and recurrence rates, but evidence quality varies across studies, particularly for specific, less common SVT subtypes.

Research Gaps and Areas of Scientific Uncertainty

While the evidence contributes to the broader evidence landscape, several limitations have been documented. The findings reflect the specific study populations, as key trial cohorts were carefully defined and selected, which means the generalizability of the findings is limited. Furthermore, long-term effects are not fully established beyond the typical follow-up durations of the key studies. Data for many comorbidity-defined groups remain insufficient.

Key Studies & References

1. Flecainide Considerations for Use - American College of Cardiology
2. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands Flecaïnideacetaat (EU Regulatory Summary)
3. Flecainide in clinical practice (Review referencing ESC Guidelines for AF and SVT)
4. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. (Specialized RCT)

Common questions about Fleco (FAQ)

Q: What is Fleco and what is it used for?

A: Fleco is a prescription medication that belongs to a class of drugs called non-steroidal anti-inflammatory drugs (NSAIDs). It is primarily used to relieve pain, tenderness, swelling, and stiffness caused by conditions such as osteoarthritis and rheumatoid arthritis in adults.

---

Q: How should I take Fleco?

A: You should take Fleco exactly as your doctor prescribes. It is typically taken by mouth, often once or twice daily, depending on your condition and the dosage. It is best to take Fleco with a full glass of water. If the medication causes stomach upset, your doctor may suggest taking it with food or milk. Do not crush, chew, or break the tablet. Swallow it whole.

---

Q: What should I do if I miss a dose of Fleco?

A: If you miss a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you are unsure, consult your doctor or pharmacist for guidance.

---

Q: What are the most common side effects of Fleco?

A: Like all medications, Fleco can cause side effects, though not everyone experiences them. The most common side effects often include:

• Upset stomach or indigestion
• Nausea or vomiting
• Diarrhea or constipation
• Gas
• Dizziness
• Headache

Contact your doctor if these side effects are persistent or worsen. Your doctor can help determine if the medication needs to be adjusted.

---

Q: Can I take other pain relievers with Fleco?

A: It is generally not recommended to take other NSAIDs (such as ibuprofen or naproxen) or aspirin for pain relief while taking Fleco. Taking multiple NSAIDs can increase the risk of serious stomach and bleeding problems. Do not take other medications without first checking with your doctor or pharmacist, as some over-the-counter pain or cold medicines may contain NSAIDs.

---

Q: Does Fleco interact with any other medications?

A: Yes, Fleco can interact with several other medications, including:

• Blood thinners (anticoagulants)
• Corticosteroids
• Diuretics
• Certain blood pressure medications (ACE inhibitors or angiotensin receptor blockers)
• Lithium

It is essential to tell your doctor about all prescription, over-the-counter, and herbal supplements you are taking before starting Fleco. This helps your doctor assess for potential interactions and adjust dosages as needed.

Storage and Disposal of Fleco (Flecainide Acetate)

Official regulatory guidelines define specific conditions to maintain the stability and integrity of flecainide acetate.

Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F), with temporary excursions allowed up to 30 C.
Protection	Store in a tight, light-resistant container. The product must be protected from light and moisture.
Child Safety	Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Official labeling directs the proper handling of unused or expired medicine. Do not dispose of Fleco via wastewater or household trash unless otherwise instructed by a local regulation or drug label.

Unused or expired product should be returned to a pharmacist or taken to an authorized drug take-back program for safe and environmentally compliant pharmaceutical waste handling.